Neuroinflammation is a driving factor in neurodegeneration and the adverse response to brain injury. For instance, individuals with Alzheimer’s disease have been shown to have reduced levels of specialized pro-resolving mediators (SPMs) in brain tissue, which are associated with cognitive function.
In this document, we describe the scientific rationale for addressing inflammation for management of neurological conditions and summarize emerging preclinical animal and cell data highlighting impact of SPMs in neurodegenerative conditions as well as in cognitive and neurological response to surgery and injury.
